incretin mimetic agents glp 1 receptor agonists GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Non-insulin injectable antidiabetic drugs -

doi: 10.3390/ijms20215407

Keywords: pediatric obesity, GLP-1 receptor agonists, semaglutide, adolescent weight management, pharmacotherapy, long-term safety, health equity, obesity treatment Introduction The global pediatric obesity epidemic represents one of the most pressing public health challenges of the 21st century

doi: 10.3389/fendo.2021.721198 23 CalsolaroVEdisonP

doi: 10.1111/dom.14280

Diets extremely high in processed foods, added sugars, and refined carbohydrates can overwhelm the appetite-suppressing effects of these medications

Most side effects are gastrointestinal and improve with thoughtful titration and diet adjustments